Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy, R.; Loi, S.; Okines, A.; Paplomata, E.; Hamilton, E.; Hurvitz, S.; Lin, N.; Borges, V.; Abramson, V.; Anders, C.; Bedard, P.; Oliveira, Mafalda; Jakobsen, E.; Bachelot, T.; S. Shachar, S.; Müller, V.; Braga, S.; Duhoux, F.; Greil, R.; Cameron, D.; Carey, L.; Curigliano, G.; Gelmon, K.; Hortobagyi, G.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; C. Palanca-Wessels, M.; Walker, L.; Feng, W.; Winer, E.

doi:10.1056/NEJMoa1914609

Public

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Shared by NobleBlocks on Dec 11, 2019 • 12:00 AM UTC

Authors:

R. Murthy

S. Loi

A. Okines

Abstract

BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyros...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!